Gilead Sciences (GILD), Glympse Bio Report Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Gilead Sciences (GILD), Glympse Bio Report Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development

Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development

October 28, 2019 8:00 AM EDT

FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gilead Sciences Inc. (Nasdaq: GILD) and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bios proprietary synthetic biomarkers bioengineered to identify stage and progression of disease as well as early detection of treatment response will be used to... More